Mar 11, 2021
Comments on ICER’s February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”. Some of the concerns raised in the letter point out that...
Sep 27, 2016
The Institute for Clinical and Economic Review, a nonprofit organization that assesses evidence on the value of medical treatments and tests, held its inaugural Midwest Comparative Effectiveness Public Advisory Council meeting on May 26. ICER’s goal was to create a...
Sep 14, 2016
Concern over rising health care costs has led to some proposals that could be dangerous for cancer patients like myself. I’ve lived with multiple myeloma, a cancer of cells in the bone marrow for the past six years, ever since it first revealed itself with a terrible...
Jun 30, 2016
ICER and cost control guru Peter Bach are slamming the brakes on innovation No matter what side of the aisle you’re on, we can all agree that medical progress should be celebrated and accelerated, not halted or even slowed. New Yorkers know this. The Big Apple is the...
May 29, 2016
Here are the takeaways from the ICER meeting on” Treatment Options for Relapsed or Refractory Multiple Myeloma”. First, it is obvious that the Midwest Comparative Effectiveness Advisory Council is nothing but a cheap coat of paint used to poorly cover-up the fact...
